CVRx Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
255
- Stock Symbol
-
CVRX
- Share Price
-
$0.63
- (As of Thursday Closing)
CVRx General Information
Description
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Contact Information
Website
www.barostim.comCorporate Office
- 9201 West Broadway Avenue
- Suite 650
- Minneapolis, MN 55445
- United States
Corporate Office
- 9201 West Broadway Avenue
- Suite 650
- Minneapolis, MN 55445
- United States
CVRx Timeline
CVRx Stock Performance
As of 12-Nov-2026, CVRx’s stock price is $0.63. Its current market cap is $17.9M with 28.5M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.63 | $0.70 | $0.63 - $10.28 | $17.9M | 28.5M | 784K | -$2.01 |
CVRx Financials Summary
As of 30-Sep-2026, CVRx has a trailing 12-month revenue of $60.3M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 41,427 | 151,493 | 257,700 | 586,831 |
| Revenue | 60,330 | 56,651 | 51,292 | 39,295 |
| EBITDA | (46,293) | (46,741) | (54,894) | (38,731) |
| Net Income | (53,261) | (53,306) | (59,965) | (41,199) |
| Total Assets | 87,612 | 104,794 | 133,414 | 115,229 |
| Total Debt | 59,385 | 50,504 | 50,432 | 30,613 |
CVRx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CVRx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
CVRx Comparisons
Industry
Financing
Details
CVRx Competitors (10)
One of CVRx’s 10 competitors is JenaValve Technology, a Private Equity-Backed company based in Irvine, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| JenaValve Technology | Private Equity-Backed | Irvine, CA | ||||
| Spine Wave | Venture Capital-Backed | Shelton, CT | ||||
| iRhythm Holdings | Formerly VC-backed | San Francisco, CA | ||||
| Colibri Heart Valve | Venture Capital-Backed | Louisville, CO | ||||
| Boston Scientific | Corporation | Marlborough, MA |
CVRx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CVRx Patents
CVRx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231553-A1 | Systems and methods for closed-loop baroreflex activation therapy using neural and/or physiological feedback | Pending | 28-Apr-2025 | ||
| US-12678627-B1 | Systems and methods for closed-loop or partially closed-loop baroreflex activation therapy | Active | 28-Apr-2025 | ||
| US-20260335649-A1 | Systems and methods for closed-loop or partially closed-loop baroreflex activation therapy | Pending | 28-Apr-2025 | ||
| US-20260295263-A1 | Baroreflex activation therapy for the treatment of secondary pulmonary hypertension | Pending | 31-Mar-2025 | ||
| US-20260249080-A1 | Systems and methods for regulating inflammation and immune responses using baroreflex activation therapy | Pending | 27-Feb-2025 | A61N1/36139 |
CVRx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CVRx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CVRx ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.93 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
CVRx FAQs
-
When was CVRx founded?
CVRx was founded in 2001.
-
Where is CVRx headquartered?
CVRx is headquartered in Minneapolis, MN.
-
What is the size of CVRx?
CVRx has 255 total employees.
-
What industry is CVRx in?
CVRx’s primary industry is Therapeutic Devices.
-
Is CVRx a private or public company?
CVRx is a Public company.
-
What is CVRx’s stock symbol?
The ticker symbol for CVRx is CVRX.
-
What is the current stock price of CVRx?
As of 12-Nov-2026 the stock price of CVRx is $0.63.
-
What is the current market cap of CVRx?
The current market capitalization of CVRx is $17.9M.
-
What is CVRx’s current revenue?
The trailing twelve month revenue for CVRx is $60.3M.
-
Who are CVRx’s competitors?
JenaValve Technology, Spine Wave, iRhythm Holdings, Colibri Heart Valve, and Boston Scientific are some of the 10 competitors of CVRx.
-
What is CVRx’s annual earnings per share (EPS)?
CVRx’s EPS for 12 months was -$2.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
